KRAS and neoplasm: By transducing HCT116 cells of wild-type or activated (G13D) KRAS with a sgRNA library targeting protein-coding genes and injecting them into mice, tumor xenografts were obtained and used to determine KRAS-lethal and enhancing mutations as well as for pathway analysis [36].